A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact

Leukemia

Volumn 29, Issue 3, 2015, Pages 598-605

  Queiros A C ^a   Villamor, N ^a   Clot, G ^a   Martinez Trillos, A ^b   Kulis, M ^a   Navarro, A ^a   Penas, E M M ^c   Jayne, S ^d   Majid, A ^d   Richter, J ^c   Bergmann, A K ^c   Kolarova, J ^c   Royo, C ^a   Russinol N ^a   Castellano, G ^a   Pinyol, M ^a   Bea, S ^a   Salaverria, I ^a   Lopez Guerra M ^a   Colomer, D ^a   Aymerich, M ^a   Rozman, M ^a   Delgado, J ^b   Gine E ^b   Gonzalez Diaz M ^e   Puente, X S ^f   Siebert, R ^c   Dyer, M J S ^g   Lopez Otin C ^f   Rozman, C ^h   Campo, E ^a   Lopez Guillermo A ^b   Martin Subero J I ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF KIEL   (Germany)

^d MRC TOXICOLOGY UNIT   (United Kingdom)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN HEAVY CHAIN; ANTINEOPLASTIC AGENT; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; INTERMEDIATE B CELL LIKE CHRONIC LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEMORY B CELL LIKE CHRONIC LYMPHATIC LEUKEMIA; NAIVE B CELL LIKE CHRONIC LYMPHATIC LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PYROSEQUENCING; SUPPORT VECTOR MACHINE; VERY ELDERLY; CLASSIFICATION; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TIME TO TREATMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SUPPORT VECTOR MACHINES; SURVIVAL ANALYSIS; TIME-TO-TREATMENT; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84924540077     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.252     Document Type: Article

References (39)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. NEngl J Med 1995; 333: 1052-1057.
2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
4. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117: 1781-1791.
5. Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44: 1236-1242.
6. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209: 2183-2198.
7. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
8. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
9. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.
10. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
11. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
12. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
13. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403-1412.
14. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
15. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
16. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev 2012; 13: 679-692.
17. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
18. Bird A. Perceptions of epigenetics. Nature 2007; 447: 396-398.
19. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L et al. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinform 2010; 11: 587.
20. Efron B, Tibshirani RJ. Improvements on cross-validation: the 632+ bootstrap method. J Am Stat Assoc 1997; 92: 548-560.
21. Cortes C, Vapnik V. Support-vector networks. Mach Learn 1995; 20: 273-297.
22. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2: 2265-2275.
23. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 2010; 16: 571-579.
24. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152-163.
25. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
26. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
27. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
28. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
29. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187-220.
30. Klein JP, Moeschberger ML. Survival Analysis. Techniques for Censored and Truncated Data. Springer: New York, NY, USA, 1997.
31. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266.
32. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339.
33. Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22: 407-419.
34. Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012; 122: 3432-3438.
35. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011; 118: 2150-2158.
36. Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013; 13: 118-132.
37. Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Malcikova J, Plevova K et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013; 27: 2196-2199.
38. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
39. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009; 114: 2044-2050.